Keyphrases
Convalescent Plasma
100%
COVID-19
84%
Type 2 Diabetic Patients
62%
Dipeptidyl peptidase-4 (DPP-4)
51%
Randomized Trial
51%
COVID-19 Convalescent Plasma
43%
Hospitalization
41%
Renal Disease
41%
Early Outpatient Treatment
41%
Cardiovascular Disease
41%
Patients with COVID-19
41%
Sulfonylurea
34%
Transfusion
28%
Clinical Trials
27%
Major Adverse Cardiovascular Events
27%
Metformin
27%
Retrospective Cohort Study
23%
Cardiovascular Safety
22%
Randomized Clinical Trial
21%
Alzheimer's Disease
20%
Symptom Resolution
20%
Individual Participant Data Meta-analysis
20%
Disease Severity
20%
Escitalopram
20%
Lower Limb Amputation
20%
Conventional Therapy
20%
Safety Monitoring
20%
Post-COVID-19 Condition
20%
Multicenter Clinical Trial
20%
Safety Reporting
20%
Flibanserin
20%
Vitamin D Supplementation
20%
Patient Portal Messaging
20%
Disproportionality Analysis
20%
Hospitalized Patients
20%
Nano-drug Delivery System
20%
Data Monitoring
20%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
20%
Cardiovascular Events
20%
Meta-analysis
20%
Nanotechnology
20%
Agitation
20%
Ocular Delivery
20%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
20%
Falls in Older Adults
20%
Antibody Treatment
20%
Inflammation
20%
Severe Disease
20%
Transfusion Reaction
20%
Symptom Duration
20%
Medicine and Dentistry
COVID-19
91%
Clinical Trial
79%
Vitamin D
41%
Patient with Type 2 Diabetes
41%
Outpatient
41%
Nephropathy
41%
Meta-Analysis
41%
Cardiovascular Disease
41%
Cardiovascular System
41%
Dipeptidyl Peptidase-4 Inhibitor
41%
Convalescence
40%
Disease
36%
Randomized Controlled Trial
33%
Randomized Clinical Trial
28%
Infection
26%
Severe Acute Respiratory Syndrome Coronavirus 2
26%
Sulfonylurea
21%
Adaptive Response
20%
Disease Severity
20%
Agents Acting on the Eye
20%
Electronic Patient Record
20%
Retrospective Cohort Study
20%
Flibanserin
20%
Blood Transfusion Reaction
20%
Public Health
20%
Chloroquine
20%
Post-Exposure Prophylaxis
20%
Patient with Alzheimer's Disease
20%
Hydroxychloroquine
20%
Systematic Review
20%
Escitalopram
20%
Alzheimer's Disease
20%
Embryo Transfer
20%
Colecalciferol
20%
Drug Delivery System
20%
Symptom
20%
Hazard Ratio
19%
Glycon
17%
Health System
13%
Supplementation
13%
Odds Ratio
11%
Adverse Event
11%
Pre-Eclampsia
10%
Placebo
8%
Health Care Cost
6%
Fall Prevention
6%
Observational Study
6%
Diabetes
6%
Urticaria
5%
Disease Exacerbation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
91%
Convalescence
71%
Non Insulin Dependent Diabetes Mellitus
62%
Dipeptidyl Peptidase IV Inhibitor
51%
Symptom
47%
Disease
43%
Kidney Disease
41%
Cardiovascular Disease
41%
SARS Coronavirus
33%
Infection
33%
Sulfonylurea
31%
Randomized Clinical Trial
31%
Coronavirinae
28%
Metformin
28%
Randomized Controlled Trial
23%
Cohort Study
23%
Vitamin D
20%
Escitalopram
20%
Hydroxychloroquine
20%
Losartan
20%
Agents Acting on the Eye
20%
Alzheimer's Disease
20%
Chloroquine
20%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Flibanserin
20%
Blood Transfusion Reaction
20%
Disproportionality Analysis
20%
Inflammation
20%
Cholecalciferol
20%
Drug Delivery System
20%
Route of Administration
20%
Cytokine
13%
Adverse Event
13%
Glucagon Like Peptide 1 Receptor Agonist
12%
Thiazolidinedione
10%
Angiotensin Receptor Antagonist
7%
Placebo
6%
Urticaria
5%
Pruritus
5%
Heart Failure
5%
Hypotension
5%
Observational Study
5%
Dipeptidyl Carboxypeptidase Inhibitor
5%
